All Stories

  1. The Prevalent New‐User Design to Study Drug–Drug Interactions: The Example of Sulfonylureas and Warfarin Interaction on the Risk of Severe Hypoglycemia
  2. Comparative risk of infection of medications used for type 2 diabetes
  3. Masking in Active Comparator Designs in Pharmacovigilance: A Retrospective Bias Analysis on the Spontaneous Reporting of Thiazolidinediones and Cardiovascular Events
  4. Opioid Use and the Risk of Ventricular Arrhythmias: A Systematic Review and Meta‐Analysis
  5. Comparators in Pharmacovigilance: A Quasi-Quantification Bias Analysis
  6. Fluoroquinolones and the risk of severe hypoglycaemia among sulphonylurea users: Population‐based cohort study
  7. Methodological Considerations on the Use of Cohort Designs in Drug-Drug Interaction Studies in Pharmacoepidemiology
  8. Effectiveness and safety of direct oral anticoagulants among patients with non-valvular atrial fibrillation and liver disease: A multinational cohort study
  9. Diagnostic Validity of Chronic Kidney Disease in Health Claims Data Over Time: Results from a Cohort of Community-Dwelling Older Adults in Germany
  10. Clinically apparent Helicobacter pylori infection and the risk of incident Alzheimer's disease: A population‐based nested case‐control study
  11. Incretin‐based drugs and the risk of diabetic retinopathy among individuals with type 2 diabetes: A systematic review and meta‐analysis of observational studies
  12. Kidney function estimators for drug dose adjustment of direct oral anticoagulants in older adults with atrial fibrillation
  13. Pharmacologic heterogeneity and risk of severe hypoglycemia with concomitant use of sulfonylureas and DPP‐4 inhibitors: population‐based cohort study
  14. Kidney Measures and Risk of Incident Heart Failure Among Older Adults
  15. Considerations on the use of different comparators in pharmacovigilance: a methodological review
  16. Use of a Statistical Adaptive Treatment Strategy Approach for Emulating Randomized Controlled Trials Using Observational Data: The Example of Blood Pressure Control Strategies for the Prevention of Cardiovascular Events Among Individuals with Hypertens...
  17. Concomitant use of statins and sodium‐glucose co‐transporter 2 inhibitors and the risk of myotoxicity reporting ‐ A disproportionality analysis
  18. Sulfonylureas versus metformin and the risk of ventricular arrhythmias among people with type 2 diabetes: a population‐based cohort study
  19. Adherence and Quality of Life in Non-Valvular Atrial Fibrillation With Direct Oral Anticoagulants Versus Vitamin K Antagonists: A Systematic Review
  20. Common vaccines and the risk of incident dementia: a population-based cohort study
  21. Concomitant Use of Sulfonylureas and β-Blockers and the Risk of Severe Hypoglycemia Among Patients With Type 2 Diabetes: A Population-Based Cohort Study
  22. Challenges in evaluating treatments for COVID-19: The case of in-hospital anticoagulant use and the risk of adverse outcomes
  23. Effectiveness and safety of direct oral anticoagulants among octogenarians with venous thromboembolism: an international multi-database cohort study
  24. Obesity as a modifier of the Cardiovascular effectiveness of Sodium-Glucose Cotransporter-2 Inhibitors in Type 2 Diabetes
  25. Concomitant Use of Sulfonylureas and Warfarin and the Risk of Severe Hypoglycemia: Population-Based Cohort Study
  26. Bleeding in women with venous thromboembolism during pregnancy: A systematic review of the literature
  27. Response to: Real‐World Data on the Risk of Ventricular Arrhythmias with Sulfonamides
  28. Investigating Potential Drug-Drug Interactions from Greek e-Prescription Data
  29. Relative effectiveness of medications for opioid-related disorders: A systematic review and network meta-analysis of randomized controlled trials
  30. 5‐Alpha Reductase Inhibitors and the Risk of Anemia among Men with Benign Prostatic Hyperplasia: A Population‐based Cohort Study
  31. Sulfonylureas and the Risk of Ventricular Arrhythmias Among People with Type 2 Diabetes: A Systematic Review of Observational Studies
  32. Effectiveness and safety of direct oral anticoagulants with antiplatelet agents in patients with venous thromboembolism: A multi‐database cohort study
  33. Pharmacoepidemiology
  34. Prescription Patterns for the Use of Antihypertensive Drugs for Primary Prevention among Patients with Hypertension in the United Kingdom
  35. Utilization and long‐term persistence of direct oral anticoagulants among patients with non‐valvular atrial fibrillation and liver disease
  36. Validity of an algorithm to identify cardiovascular deaths from administrative health records: a multi-database population-based cohort study
  37. The Modifying Effects of Adiposity on the Cardiovascular Safety of Sulfonylureas
  38. Infectious Disease Burden and the Risk of Alzheimer’s Disease: A Population-Based Study
  39. Potential drug-drug interaction between sodium-glucose co-transporter 2 inhibitors and statins: pharmacological and clinical evidence
  40. Global COVID ‐19 Pandemic and Reporting Behavior ‐ An Analysis of the Food and Drug Administration Adverse Events Reporting System ( FAERS )
  41. Effectiveness and safety of direct oral anticoagulants in patients with cancer associated venous thromboembolism
  42. Domperidone and the Risks of Sudden Cardiac Death and Ventricular Arrhythmia: A Systematic Review and Meta‐Analysis of Observational Studies
  43. Tyrosine kinase inhibitors targeting vascular endothelial growth factor and the risk of aortic dissection—A pharmacovigilance analysis
  44. Control of blood pressure in older patients with heart failure and the risk of mortality: a population-based prospective cohort study
  45. Sodium-glucose co-transporter 2 inhibitors and the risk of venous thromboembolism in patients with type 2 diabetes: a cohort study
  46. Sodium glucose cotransporter 2 inhibitors and risk of major adverse cardiovascular events: multi-database retrospective cohort study
  47. Sodium–Glucose Cotransporter 2 Inhibitors and the Risk of Below-Knee Amputation: A Multicenter Observational Study
  48. Author response: Degree of serotonin reuptake inhibition of antidepressants and ischemic risk: A cohort study
  49. Sodium–Glucose Cotransporter-2 Inhibitors and the Risk for Diabetic Ketoacidosis
  50. Sodium‐glucose Cotransporter 2 Inhibitors and the Risk for Urosepsis – A Multi‐site Prevalent New‐user Cohort Study
  51. Direct oral anticoagulants and oesophageal disorders: a pharmacovigilance analysis
  52. Self-reported medication in community-dwelling older adults in Germany: results from the Berlin Initiative Study
  53. Comparative cardiovascular and hypoglycemic safety of glimepiride in type 2 diabetes: A population‐based cohort study
  54. Degree of serotonin reuptake inhibition of antidepressants and ischemic risk
  55. Sodium–Glucose Cotransporter 2 Inhibitors and the Risk of Fractures Among Patients With Type 2 Diabetes
  56. Sulfonylureas as Initial Treatment for Type 2 Diabetes and the Risk of Adverse Cardiovascular Events: A Population‐based Cohort Study
  57. Opioids and the Risk of Infection: A Critical Appraisal of the Pharmacologic and Clinical Evidence
  58. Dipeptidyl Peptidase 4 Inhibitors and the Risk of Bullous Pemphigoid Among Patients With Type 2 Diabetes
  59. Comparative Effectiveness and Safety of Direct Oral Anticoagulants in Patients with Atrial Fibrillation: A Systematic Review and Meta-Analysis of Observational Studies
  60. Reviewing the effects of thiazide and thiazide-like diuretics as photosensitizing drugs on the risk of skin cancer
  61. RE: Metformin Use and Gastric Cancer Risk in Diabetic Patients After Helicobacter pylori Eradication
  62. Control of blood pressure and risk of mortality in a cohort of older adults: the Berlin Initiative Study
  63. What Fluoroquinolones Have the Highest Risk of Aortic Aneurysm? A Case/Non-case Study in VigiBase®
  64. Incretin based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes: population based cohort study
  65. Concomitant Use of Direct Oral Anticoagulants with Antiplatelet Agents and the Risk of Major Bleeding in Patients with Nonvalvular Atrial Fibrillation
  66. Glucagon-Like Peptide 1 Receptor Agonists and the Risk of Incident Diabetic Retinopathy
  67. Sulfonylureas as second line drugs in type 2 diabetes and the risk of cardiovascular and hypoglycaemic events: population based cohort study
  68. Use of dipeptidyl peptidase-4 inhibitors and new-onset rheumatoid arthritis in patients with type 2 diabetes
  69. Dipeptidyl peptidase-4 inhibitors and incidence of inflammatory bowel disease among patients with type 2 diabetes: population based cohort study
  70. Risk of Intracranial Hemorrhage Associated with the Use of Antidepressants Inhibiting Serotonin Reuptake: A Systematic Review
  71. Non–Vitamin K Antagonist Oral Anticoagulants and Risk of Serious Liver Injury
  72. Single-Pill Triple Fixed Dose Combination Therapy with Single Component Drug Monitoring in Treatment-Resistant Hypertension: A Pilot Study
  73. Drug-induced kidney injury: A large case series from the Berlin Case-Control Surveillance Study

  74. Patterns of long-term use of non-vitamin K antagonist oral anticoagulants for non-valvular atrial fibrillation: Quebec observational study
  75. Pharmacologic Differences of Sulfonylureas and the Risk of Adverse Cardiovascular and Hypoglycemic Events
  76. Immobilization and high platelet count are associated with thromboembolic complications in heparin-induced thrombocytopenia
  77. Tocilizumab-induced pancreatitis: case report and review of data from the FDA Adverse Event Reporting System
  78. Risk of venous thromboembolism in cancer patients treated with epoetins or blood transfusions
  79. Pharmakovigilanz in Deutschland
  80. Herb-Induced Liver Injury in the Berlin Case-Control Surveillance Study
  81. Drug–drug interactions and safety of linezolid, tedizolid, and other oxazolidinones
  82. Drug-induced liver injury: results from the hospital-based Berlin Case-Control Surveillance Study
  83. Estimating kidney function and use of oral antidiabetic drugs in elderly
  84. Safety issues and drug–drug interactions with commonly used quinolones
  85. Insufficient anticoagulation with dabigatran in a patient with short bowel syndrome
  86. Flupirtine-induced liver injury—Seven cases from the Berlin Case–control Surveillance Study and review of the German spontaneous adverse drug reaction reporting database
  87. Drug-induced acute pancreatitis: results from the hospital-based Berlin case-control surveillance study of 102 cases
  88. Ramipril-Induced Liver Injury: Case Report and Review of the Literature